Heart failure & cardiomyopathies
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
Authors' conclusion
In patients with HF, dapagliflozin significantly improves symptoms and physical limitations after 12 weeks of treatment, with consistent and clinically meaningful benefits across the full range of EF.
Study context
- Population
- Patients with heart failure (HF) across the full range of ejection fraction (EF) (DEFINE-HF EF ≤40%; PRESERVED-HF EF ≥45%), NYHA class II or higher and elevated natriuretic peptides
- Participants
- 587 patients
- Comparison
- Dapagliflozin vs placebo
- Dapagliflozinn = 293
- Placebon = 294reference
- Outcome
- Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
- Follow-up
- 12 weeks
Methodological detailsdouble-blind, placebo-controlled, 12-week trials
- Double-blind
- Placebo-controlled
- 12-week trials
Pooled result
As reported in the abstract
KCCQ-CSS change
Dapagliflozin vs PlaceboPlacebo-adjusted difference, points (95% CI)P value
Overall
5.0(2.6–7.5)
P < 0.001EF≤40%
4.6(1.0–8.1)
P = 0.01EF >40 to ≤60%
4.9(0.8–9.0)
P = 0.02EF >60%
6.8(1.5–12.1)
P = 0.01Further pooled results
KCCQ-CSS responder analyses (deterioration; small, moderate, large improvements)
- Fewer dapagliflozin-treated patients had deterioration and more had small, moderate and large KCCQ-CSS improvements vs placebo, consistent regardless of EF
- All interaction P values nonsignificant
Original publication
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Circ Heart Fail. Published 19 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →